$OKLO

Cochran Caroline sold $3.1M of OKLO

Cochran Caroline (Co-Founder, COO) sold 60,000 shares of Oklo Inc. (OKLO) at $52.30 ($3.14M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cochran Caroline
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

A co-founder/COO selling shares under a pre-arranged 10b5-1 plan is generally not a standalone fundamental trigger, but it can slightly influence short-term sentiment.

02

Market read

Traders may monitor whether this sale is part of a larger planned schedule, but the disclosed event itself is unlikely to drive a major repricing.

03

What to watch

The filing does not disclose reasons for sale, and the net holdings after the transaction remain substantial (478,039 shares), limiting inference.

Relevance 5/10Novelty 3/10Timing: filed July 2, transaction dated July 1

Background

The article is an SEC Form 4 insider transaction disclosure for Oklo Inc.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder and COO Cochran Caroline filed a Form 4 selling 60,000 shares at $52.30 on July 1 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be modest and short-lived unless follow-on selling accelerates.

Evidence & confidence

Form 4 details a single open-market sale executed under a pre-arranged Rule 10b5-1 plan, which typically reduces the informational content versus discretionary selling.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can be purely liquidity-driven and may not reflect bearish expectations.

Key entities

  • Oklo Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Cochran Caroline

    Co-founder and COO, reported an open-market sale under a 10b5-1 plan.

Related articles

$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.